SAN Sanofi

Sanofi: Information concerning the total number of voting rights and shares - August 2024

Sanofi: Information concerning the total number of voting rights and shares - August 2024

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)

Sanofi

a French société anonyme with a registered share capital of 2,537,214,304 €

Registered office : 46, avenue de la Grande Armée - 75017 Paris - France

Registered at the Paris Commercial and Companies Registry under number 395 030 844

Date 



Total number of

issued shares



 		Number of real

voting rights

(excluding treasury shares)		Theoretical number of

voting rights

(including treasury shares)*
August 31, 20241,268,767,8761,413,467,8421,428,801,485

* Pursuant to article 223-11 of the Règlement général de l’Autorité des Marchés Financiers.

This information is also available on the internet website of sanofi under « Regulated Information in France »:

Investor Relations Department

e-mail:



 



 

Attachment



EN
16/09/2024

Underlying

SANSanofi

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sanofi

 PRESS RELEASE
Free
SAN SANOFI

Press Release: Dupixent recommended for EU approval by the CHMP to tre...

Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old Recommendation based on a phase 3 study showing a significantly greater proportion of children on Dupixent achieved histological remission, compared to placebo, consistent with improvements seen in adults and adolescentsIf approved, Dupixent would be the first and only medicine in the EU indicated for EoE in this age group Paris ...

5h / 56m 1 EN
 PRESS RELEASE
Free
SAN SANOFI

Communiqué de presse : Le CHMP recommande l’approbation du Dupixent da...

Communiqué de presse : Le CHMP recommande l’approbation du Dupixent dans l’UE pour le traitement de l’œsophagite à éosinophiles de l’enfant à partir de 12 mois   Le CHMP recommande l’approbation du Dupixent dans l’UE pour le traitement de l’œsophagite à éosinophiles de l’enfant à partir de 12 mois Recommandation fondée sur une étude de phase III ayant montré qu’une proportion significativement plus importante d’enfants traités par Dupixent a présenté une rémission histologique, comparativement à ceux traités par placebo, à l’instar des améliorations observées chez les adultes et ado...

5h / 56m 1 EN
 PRESS RELEASE
Free
SAN SANOFI

Press Release: Tolebrutinib demonstrated a 31% delay in time to onset ...

Press Release: Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study Data presented at ECTRIMS show that tolebrutinib, a brain-penetrant BTK inhibitor, addresses disability accumulation that occurs independently from relapse activityGlobal regulatory submissions will begin in H2 2024 Paris, September 20, 202...

8h / 11m 1 EN
 PRESS RELEASE
Free
SAN SANOFI

CP : Le tolebrutinib a permis d’allonger de 31 % le délai avant progre...

CP : Le tolebrutinib a permis d’allonger de 31 % le délai avant progression confirmée du handicap dans le cadre d’une étude de phase III menée chez des personnes présentant une sclérose en plaques secondairement progressive non active Le tolebrutinib a permis d’allonger de 31 % le délai avant progression confirmée du handicap dans le cadre d’une étude de phase III menée chez des personnes présentant une sclérose en plaques secondairement progressive non active Les données présentées au Congrès de l’ECTRIMS montrent que le tolebrutinib, un inhibiteur de la BTK à pénétration cérébrale, r...

8h / 11m 1 EN
 PRESS RELEASE
Free
SAN SANOFI

Sanofi: Information concerning the total number of voting rights and s...

Sanofi: Information concerning the total number of voting rights and shares - August 2024 Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of 2,537,214,304 €Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Registry u...

September 16, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch